Clinical trials: Meningoencephalitis
West Nile Fever
An Exploratory Study of AVI-4020 in Patients With Possible Acute Neuroinvasive West Nile Virus (WNV) Disease
Although the serious form of West Nile Virus (WNV) disease, referred to as neuroinvasive disease, is rare, it can result in permanent disabilities and occasionally death.
- Trial name
- NCT00091845
- Testing
- AVI-4020 Injection
- Volunteers
- 50 people
- Sponsor
- Sarepta Therapeutics, Inc.
Neuropsychiatric Systemic Lupus Erythematosus, Systemic Lupus Erythematosus (SLE)
EG-501 for Cognitive Impairment in Neuropsychiatric SLE (NPSLE): Efficacy and Safety Study
Neuropsychiatric systemic lupus erythematosus with cognitive impairment (NPSLE-CI) is a serious, disabling, and potentially life-threatening manifestation of SLE, affecting up to 80% of patients with cognitive impairments ("brain…
- Conditions
- Neuropsychiatric Systemic Lupus Erythematosus, Systemic Lupus Erythematosus (SLE), Cognitive Impairment
- Trial name
- NCT07281105
- Testing
- EG-501
- Where
- 3 sites in United States
- Volunteers
- 131 people
- Sponsor
- Evergreen Therapeutics, Inc.
West Nile Virus
Pharmacokinetic Study in Cerebral Spinal Fluid After a Single Dose of AVI-4020
During a clinical study of people with severe West Nile virus infections, it was determined that the drug AVI-4020 crossed the blood-brain barrier.
- Trial name
- NCT00387283
- Testing
- AVI-4020 Injection
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Sarepta Therapeutics, Inc.
Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Discoid
Phase Ib Study of SC Milatuzumab in SLE
Milatuzumab will be given subcutaneously at different dose levels once (depending on the dose level) for 4 weeks to determine if milatuzumab helps to control lupus (SLE).
- Conditions
- Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Discoid, Lupus Erythematosus, Systemic, Lupus Vasculitis, Central Nervous System
- Trial name
- NCT01845740
- Testing
- milatuzumab
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Gilead Sciences